Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.36 |
| ▸ | MPO | P05164 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 2/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | NSD2 | O96028 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL676346 | 0.64 | NR4A1 (0.35) | P2RX7KDM4EMPOCYP3A4CYP1A2 | |
| SCHEMBL1627167 | 0.61 | MPO (0.32) | P2RX7KDM4EMPOCYP3A4CYP1A2 | |
| SCHEMBL6436117 | 0.59 | — | — | |
| SCHEMBL28723691 | 0.57 | KDM4E (0.44) | P2RX7KDM4EMPOCYP3A4CYP1A2 | |
| SCHEMBL2635238 | 0.57 | HDAC1 (0.69) | P2RX7KDM4EMPOCYP3A4CYP1A2 | |
| SCHEMBL11134828 | 0.56 | MPO (0.70) | KDM4EMPOCYP3A4CYP1A2ADORA3 | |
| SCHEMBL31377918 | 0.56 | P2RX7 (0.52) | P2RX7KDM4EMPOCYP3A4CYP1A2 | |
| SCHEMBL13169723 | 0.56 | P2RX7 (0.56) | P2RX7KDM4EMPOCYP3A4CYP1A2 | |
| SCHEMBL1893743 | 0.56 | KDM4E (0.68) | P2RX7KDM4EMPOCYP3A4CYP1A2 | |
| SCHEMBL2678949 | 0.56 | MPO (0.80) | KDM4EMPOCYP3A4CYP1A2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021254347-A1 | VALVE MATERIAL HAVING LONG-ACTING ANTITHROMBOSIS PROPERTY AND PREPARATION METHOD THEREFOR | 杭州启明医疗器械股份有限公司 | 2021-12-23 | — | — | WO | claimed |
| CN-104211815-B | A kind of ferritin heavy chain subunit nano medicament carrying system and preparation method and application | 华东理工大学 | 2017-06-06 | — | — | CN | claimed |
| CN-104211815-A | Ferritin heavy chain subunit nano medicament carrying system as well as preparation method and application thereof | UNIV EAST CHINA SCIENCE & TECH | 2014-12-17 | — | — | CN | claimed |
| EP-1353937-A4 | SPECIFIC HUMAN ANTIBODIES FOR SELECTIVE CANCER THERAPY | SAVIENT PHARMACEUTICALS INC (US) | 2005-04-13 | — | — | EP | claimed |
| EP-1353937-A2 | SPECIFIC HUMAN ANTIBODIES FOR SELECTIVE CANCER THERAPY | BIO-TECHNOLOGY GENERAL CORPORATION (US) | 2003-10-22 | — | — | EP | claimed |
| WO-2002059264-A2 | SPECIFIC HUMAN ANTIBODIES FOR SELECTIVE CANCER THERAPY | BIO-TECHNOLOGY GENERAL CORP. (US) | 2002-08-01 | — | — | WO | claimed |
| US-12016913-B2 | Immunogenic compositions and uses thereof | PFIZER INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018134-B2 | Processes for preparing dried polysaccharides | GLAXOSMITHKLINE BIOLOGICAL SA (BE) | 2024-06-25 | — | — | US | disclosed |
| US-20230391794-A1 | MAYTANSINOID-BASED DRUG DELIVERY SYSTEMS | CENTURION BIOPHARMA CORPORATION | 2023-12-07 | — | — | US | disclosed |
| US-20230346903-A1 | GROUP B STREPTOCOCCUS POLYSACCHARIDE-PROTEIN CONJUGATES, METHODS FOR PRODUCING CONJUGATES, IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATES, AND USES THEREOF | PFIZER INC. (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230321212-A1 | GROUP B STREPTOCOCCUS POLYSACCHARIDE-PROTEIN CONJUGATES, METHODS FOR PRODUCING CONJUGATES, IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATES, AND USES THEREOF | PFIZER (US) | 2023-10-12 | — | — | US | disclosed |
| EP-4203995-A1 | GROUP B STREPTOCOCCUS POLYSACCHARIDE-PROTEIN CONJUGATES, METHODS FOR PRODUCING CONJUGATES, IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATES, AND USES THEREOF | Pfizer Inc. (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-114010775-A | Group B streptococcal polysaccharide-protein conjugates, methods of making conjugates, immunogenic compositions containing conjugates, and uses thereof | 辉瑞大药厂 | 2022-02-08 | — | — | CN | disclosed |
| US-20030083263-A1 | Pentapeptide compounds and uses related thereto | SEATTLE GENETICS INCORPORATED | 2003-05-01 | — | — | US | disclosed |
| WO-2002088172-A2 | PENTAPEPTIDE COMPOUNDS AND USES RELATED THERETO | SEATTLE GENETICS, INC. (US) | 2002-11-07 | — | — | WO | disclosed |
| US-6124435-A | HIV INFECTED CELLS CAN BE DETECTED USING CONJUGATES THAT INCLUDE CD4 MOLECULES CONJUGATED TO DETECTABLE MARKERS VIA THE DISCLOSED CROSS-LINKING REAGENTS | GENETECH, INC. (US) | 2000-09-26 | — | — | US | disclosed |
| US-5929211-A | A CONJUGATE MOLECULE HAVING A GLYCOPROTEIN COVALENTLY ATTACHED TO A THIOL-CONTAINING TOXIN THROUGH A COMPOUND HAVING HYDRAZIDE AND THE MALEIMIDE MOIETIES FOR DETECTING HUMAN IMMUNODEFICIENCY VIRUS INFECTED CELLS | GENENTECH, INC. (US) | 1999-07-27 | — | — | US | disclosed |
| US-5889155-A | Carbohydrate-directed cross-linking reagents | GENENTECH, INC. (US) | 1999-03-30 | — | — | US | disclosed |
| US-5605791-A | DETECTING HUMAN IMMUNODEFICIENCY VIRUS INFECTED CELLS BY CONTACTING WITH CONJUGATE OF CD4 MOLECULE LINKED TO DETECTABLE MARKER BY COMPOUND HAVING MALEIMIDE AND HYDRAZIDE GROUPS, DETECTING SIGNAL | GENENTECH, INC. (US) | 1997-02-25 | — | — | US | disclosed |
| US-5329028-A | Couplers for aldehydes and thiols | GENENTECH, INC. (US) | 1994-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391794-A1 | MAYTANSINOID-BASED DRUG DELIVERY SYSTEMS | SLC6A2, SLC6A7, SLC6A4 | P2RX7 3165/4885KDM4E 4280/4885MPO 3852/4885 |
| US-20030083263-A1 | Pentapeptide compounds and uses related thereto | NGLY1, VIP, DNPEP | P2RX7 2832/4885KDM4E 4594/4885MPO 1893/4885 |
| US-20230321212-A1 | GROUP B STREPTOCOCCUS POLYSACCHARIDE-PROTEIN CONJUGATES, METHODS FOR PRODUCING CONJUGATES, IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATES, AND USES THEREOF | SIGLEC7, SIGLEC9, FCGR3B | P2RX7 2994/4885KDM4E 2536/4885MPO 1386/4885 |
| US-12016913-B2 | Immunogenic compositions and uses thereof | FCGR3B, SIGLEC7, SIGLEC9 | P2RX7 1231/4885KDM4E 3728/4885MPO 2260/4885 |
| US-20230346903-A1 | GROUP B STREPTOCOCCUS POLYSACCHARIDE-PROTEIN CONJUGATES, METHODS FOR PRODUCING CONJUGATES, IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATES, AND USES THEREOF | SIGLEC7, SIGLEC9, FCGR3B | P2RX7 2920/4885KDM4E 2366/4885MPO 1597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.